JANX

Janux Therapeutics, Inc.

8.99 USD

Last updated Dec 3, 04:34 UTC

Yesterday HIGH

$9.25

Yesterday LOW

$8.12

52w HIGH

$23.64

52w LOW

$5.65

EPS

-0.25

PE

-35.96

Next Earnings

Mar 8, 2024

Overview News Insider Transactions Government Trades

Janux Therapeutics, Inc. stock is up 32.79% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

januxrx.com

richadhand@benzinga.com

Wed May 10, 2023

HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains $35 price target.
Benzinga Insights

Tue May 9, 2023

Janux Therapeutics: Q1 Earnings Insights
Benzinga Newsdesk

Tue May 9, 2023

Janux Therapeutics Q1 EPS $(0.42) Beats $(0.49) Estimate, Sales $2.05M

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.49) by 14.29 percent. This is a 31.25 percent decrease over losses of $(0.32) per share
Happy Mohamed

Thu Apr 20, 2023

Janux Therapeutics Announces First Patient Dosed With JANX008 In First-In-Human Phase 1 Clinical Trial In Patients With Solid Tumors

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell
Benzinga Insights

Thu Apr 6, 2023

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
richadhand@benzinga.com

Thu Apr 6, 2023

Wedbush Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $24

Wedbush analyst Robert Driscoll initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating and announces Price Target of $24.
richadhand@benzinga.com

Mon Mar 13, 2023

HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains $35 price target.
Michael Horton

Fri Mar 10, 2023

Janux Therapeutics Q4 EPS $(0.39) Beats $(0.49) Estimate, Sales $2.85M Beat $790.00K Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.49) by 20.41 percent. This is a 18.18 percent decrease over losses of $(0.33) per share
Benzinga Insights

Thu Feb 9, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Lisa Levin

Wed Feb 1, 2023

Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit management.

HC Wainwright & Co.

Mon Nov 13, 10:43

buy

confirm
Wedbush

Wed Nov 8, 08:54

buy

confirm

Advanced Data Unlock

Reardon Tighe, Acting Chief Financial Officer

Mon Nov 13, 2023

JANX Recent Insider Trades and Stock Chart

849,854 shares bought
Lichter Jay, Director

Mon Nov 13, 2023

JANX Recent Insider Trades and Stock Chart

849,854 shares bought
Avalon Ventures XI, L.P., 10% Owner

Mon Nov 13, 2023

JANX Recent Insider Trades and Stock Chart

849,854 shares bought